Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
pubmed:
30
4
2020
medline:
24
6
2021
entrez:
30
4
2020
Statut:
ppublish
Résumé
Anhedonia is thought to reflect deficits in reward processing that are associated with abnormal activity in mesocorticolimbic brain regions. It is expressed clinically as a deficit in the interest or pleasure in daily activities. More severe anhedonia in major depressive disorder (MDD) is a negative predictor of antidepressant response. It is unknown, however, whether the pathophysiology of anhedonia represents a viable avenue for identifying biological markers of antidepressant treatment response. Therefore, this study aimed to examine the relationships between reward processing and response to antidepressant treatment using clinical, behavioral, and functional neuroimaging measures. Eighty-seven participants in the first Canadian Biomarker Integration Network in Depression (CAN-BIND-1) protocol received 8 weeks of open-label escitalopram. Clinical correlates of reward processing were assessed at baseline using validated scales to measure anhedonia, and a monetary incentive delay (MID) task during functional neuroimaging was completed at baseline and after 2 weeks of treatment. Response to escitalopram was associated with significantly lower self-reported deficits in reward processing at baseline. Activity during the reward anticipation, but not the reward consumption, phase of the MID task was correlated with clinical response to escitalopram at week 8. Early (baseline to week 2) increases in frontostriatal connectivity during reward anticipation significantly correlated with reduction in depressive symptoms after 8 weeks of treatment. Escitalopram response is associated with clinical and neuroimaging correlates of reward processing. These results represent an important contribution towards identifying and integrating biological, behavioral, and clinical correlates of treatment response. ClinicalTrials.gov: NCT01655706.
Identifiants
pubmed: 32349119
doi: 10.1038/s41386-020-0688-x
pii: 10.1038/s41386-020-0688-x
pmc: PMC7297974
doi:
Substances chimiques
Biomarkers
0
Citalopram
0DHU5B8D6V
Banques de données
ClinicalTrials.gov
['NCT01655706']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1390-1397Subventions
Organisme : CIHR
Pays : Canada
Références
Vrieze E, Pizzagalli DA, Demyttenaere K, Hompes T, Sienaert P, de Boer P, et al. Reduced reward learning predicts outcome in major depressive disorder. Biol Psychiatry. 2013;73:639–45.
pubmed: 23228328
Spijker J, Bijl RV, de Graaf R, Nolen WA. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand. 2001;103:122–30.
pubmed: 11167315
Downar J, Geraci J, Salomons TV, Dunlop K, Wheeler S, McAndrews MP, et al. Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. Biol Psychiatry. 2014;76:176–85.
pubmed: 24388670
Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449–59.
pubmed: 18221624
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.
pubmed: 17074942
pmcid: 17074942
Hägele C, Schlagenhauf F, Rapp M, Sterzer P, Beck A, Bermpohl F, et al. Dimensional psychiatry: reward dysfunction and depressive mood across psychiatric disorders. Psychopharmacology. 2015;232:331–41.
pubmed: 24973896
Dubol M, Trichard C, Leroy C, Sandu A-L, Rahim M, Granger B, et al. Dopamine transporter and reward anticipation in a dimensional perspective: a multimodal brain imaging study. Neuropsychopharmacology. 2018;43:820–7.
pubmed: 28829051
Stoy M, Schlagenhauf F, Sterzer P, Bermpohl F, Hägele C, Suchotzki K, et al. Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram. J Psychopharmacol. 2012;26:677–88.
pubmed: 21926423
Dichter GS, Kozink RV, McClernon FJ, Smoski MJ. Remitted major depression is characterized by reward network hyperactivation during reward anticipation and hypoactivation during reward outcomes. J Affect Disord. 2012;136:1126–34.
pubmed: 22036801
Zhang B, Lin P, Shi H, Öngür D, Auerbach RP, Wang X, et al. Mapping anhedonia-specific dysfunction in a transdiagnostic approach: an ALE meta-analysis. Brain Imaging Behav. 2016;10:920–39.
pubmed: 26487590
Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, et al. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry. 2009;166:702–10.
pubmed: 19411368
pmcid: 2735451
Admon R, Nickerson LD, Dillon DG, Holmes AJ, Bogdan R, Kumar P, et al. Dissociable cortico-striatal connectivity abnormalities in major depression in response to monetary gains and penalties. Psychol Med. 2015;45:121–31.
pubmed: 25055809
Wacker J, Dillon DG, Pizzagalli DA. The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: integration of resting EEG, fMRI, and volumetric techniques. Neuroimage. 2009;46:327–37.
pubmed: 19457367
pmcid: 2686061
Prakash N, Stark CJ, Keisler MN, Luo L, Der-Avakian A, Dulcis D. Serotonergic plasticity in the dorsal raphe nucleus characterizes susceptibility and resilience to anhedonia. J Neurosci. 2020;40:569–84.
pubmed: 31792153
Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017;23:28–38.
pubmed: 27918562
pmcid: 27918562
Carl H, Walsh E, Eisenlohr-Moul T, Minkel J, Crowther A, Moore T, et al. Sustained anterior cingulate cortex activation during reward processing predicts response to psychotherapy in major depressive disorder. J Affect Disord. 2016;203:204–12.
pubmed: 27295377
pmcid: 5651145
Walsh E, Carl H, Eisenlohr-Moul T, Minkel J, Crowther A, Moore T, et al. Attenuation of frontostriatal connectivity during reward processing predicts response to psychotherapy in major depressive disorder. Neuropsychopharmacology. 2017;42:831–43.
pubmed: 27585739
Kujawa A, Burkhouse KL, Karich SR, Fitzgerald KD, Monk CS, Phan KL. Reduced reward responsiveness predicts change in depressive symptoms in anxious children and adolescents following treatment. J Child Adolesc Psychopharmacol. 2019;29:378–85.
pubmed: 31062997
pmcid: 6585168
Forbes EE, Olino TM, Ryan ND, Birmaher B, Axelson D, Moyles DL, et al. Reward-related brain function as a predictor of treatment response in adolescents with major depressive disorder. Cogn Affect Behav Neurosci. 2010;10:107–18.
pubmed: 20233959
pmcid: 2841787
Admon R, Kaiser RH, Dillon DG, Beltzer M, Goer F, Olson DP, et al. Dopaminergic enhancement of striatal response to reward in major depression. Am J Psychiatry. 2017;174:378–86.
pubmed: 27771973
Cheng Y, Xu J, Arnone D, Nie B, Yu H, Jiang H, et al. Resting-state brain alteration after a single dose of SSRI administration predicts 8-week remission of patients with major depressive disorder. Psychol Med. 2017;47:438–50.
pubmed: 27697079
Burkhouse KL, Gorka SM, Klumpp H, Kennedy AE, Karich S, Francis J, et al. Neural responsiveness to reward as an index of depressive symptom change following cognitive-behavioral therapy and SSRI treatment. J Clin Psychiatry. 2018;79:17m11836.
pubmed: 29894598
pmcid: 6527365
Allen TA, Lam RW, Milev R, Rizvi SJ, Frey BN, MacQueen GM, et al. Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychol Med. 2019;49:1629–38.
pubmed: 30220263
Whitton AE, Webb CA, Dillon DG, Kayser J, Rutherford A, Goer F, et al. Pretreatment rostral anterior cingulate cortex connectivity with salience network predicts depression recovery: findings from the EMBARC randomized clinical trial. Biol Psychiatry 2019;85:872–80.
pubmed: 30718038
Kennedy SH, Lam RW, Rotzinger S, Milev RV, Blier P, Downar J, et al. Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjunctive aripiprazole therapy in patients with major depressive disorder: a CAN-BIND-1 report. J Clin Psychiatry. 2019;80:18m12202.
pubmed: 30840787
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
pubmed: 444788
pmcid: 444788
Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167:99–103.
pubmed: 7551619
Rizvi SJ, Quilty LC, Sproule BA, Cyriac A, Michael Bagby R, Kennedy SH. Development and validation of the Dimensional Anhedonia Rating Scale (DARS) in a community sample and individuals with major depression. Psychiatry Res. 2015;229:109–19.
pubmed: 26250147
Alders GL, Davis AD, MacQueen G, Strother SC, Hassel S, Zamyadi M, et al. Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. J Affect Disord. 2019;257:765–73.
pubmed: 31400735
Knutson B, Bhanji JP, Cooney RE, Atlas LY, Gotlib IH. Neural responses to monetary incentives in major depression. Biol Psychiatry. 2008;63:686–92.
pubmed: 17916330
Schiller CE, Minkel J, Smoski MJ, Dichter GS. Remitted major depression is characterized by reduced prefrontal cortex reactivity to reward loss. J Affect Disord. 2013;151:756–62.
pubmed: 23835103
pmcid: 3797197
Smoski MJ, Rittenberg A, Dichter GS. Major depressive disorder is characterized by greater reward network activation to monetary than pleasant image rewards. Psychiatry Res. 2011;194:263–70.
pubmed: 22079658
pmcid: 3225489
MacQueen GM, Hassel S, Arnott SR, Jean A, Bowie CR, Bray SL, et al. The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. J Psychiatry Neurosci. 2019;44:223–36.
pubmed: 30840428
pmcid: 6606427
Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL. Neuroimage 2012;62:782–90.
pubmed: 21979382
Costumero V, Barrós-Loscertales A, Bustamante JC, Ventura-Campos N, Fuentes P, Ávila C. Reward sensitivity modulates connectivity among reward brain areas during processing of anticipatory reward cues. Eur J Neurosci. 2013;38:2399–407.
pubmed: 23617942
Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968–80.
pubmed: 16530430
Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med. 2012;42:967–80.
pubmed: 21929846
Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996;67:588–97.
pubmed: 8991972
Hamilton MC. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
pubmed: 495331
pmcid: 495331
Baskaran A, Farzan F, Milev R, Brenner CA, Alturi S, Pat McAndrews M, et al. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: a pilot study. J Affect Disord. 2018;227:542–9.
pubmed: 29169123
Wagner S, Engel A, Engelmann J, Herzog D, Dreimüller N, Müller MB, et al. Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systematic review and meta-analysis. J Psychiatr Res. 2017;94:96–106.
pubmed: 28697423
Olgiati P, Serretti A, Souery D, Dold M, Kasper S, Montgomery S, et al. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. J Affect Disord. 2018;227:777–86.
pubmed: 29254066
Hunter AM, Nghiem TX, Cook IA, Krantz DE, Minzenberg MJ, Leuchter AF. Change in quantitative EEG theta cordance as a potential predictor of repetitive transcranial magnetic stimulation clinical outcome in major depressive disorder. Clin EEG Neurosci. 2018;49:306–15.
pubmed: 29224411
Karim HT, Wang M, Andreescu C, Tudorascu D, Butters MA, Karp JF, et al. Acute trajectories of neural activation predict remission to pharmacotherapy in late-life depression. NeuroImage Clin. 2018;19:831–9.
pubmed: 30013927
pmcid: 6024196
Targum SD. Early symptomatic improvement affects treatment outcome in a study of major depressive disorder. J Psychiatr Res. 2017;95:276–81.
pubmed: 28926793
Khan A, Cohen S, Dager S, Avery DH, Dunner DL. Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. J Affect Disord. 1989;17:33–8.
Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry. 1984;41:782–6.
pubmed: 6378117
Kemp DE, Ganocy SJ, Brecher M, Carlson BX, Edwards S, Eudicone JM, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011;130:171–9.
pubmed: 21071096
Knutson B, Westdorp A, Kaiser E, Hommer D. FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage. 2000;12:20–7.
pubmed: 10875899
Wilson RP, Colizzi M, Bossong MG, Allen P, Kempton M, MTAC, et al. The neural substrate of reward anticipation in health: a meta-analysis of fMRI findings in the monetary incentive delay task. Neuropsychol Rev. 2018;28:496–506.
pubmed: 30255220
pmcid: 6327084
Sankar A, Yttredahl AA, Fourcade EW, Mickey BJ, Love TM, Langenecker SA, et al. Dissociable neural responses to monetary and social gain and loss in women with major depressive disorder. Front Behav Neurosci. 2019;13:149.
pubmed: 31354443
pmcid: 6637282
Dillon DG, Bogdan R, Fagerness J, Holmes AJ, Perlis RH, Pizzagalli DA. Variation in TREK1 gene linked to depression-resistant phenotype is associated with potentiated neural responses to rewards in humans. Hum Brain Mapp. 2010;31:210–21.
pubmed: 19621370